Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions

Area of Science:

• Nephrology
• Molecular Biology
• Physiology

Background:

• Chronic kidney disease (CKD) is a catabolic condition marked by muscle wasting and reduced endurance.
• Muscle wasting in CKD results from an imbalance between protein degradation and synthesis.
• Elevated reactive oxygen species (ROS), inflammatory cytokines, and specific uremic toxins contribute to muscle atrophy.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying muscle wasting and decreased endurance in CKD.
• To investigate the role of specific uremic toxins, such as indoxyl sulfate, in CKD-related muscle atrophy.
• To explore potential therapeutic strategies targeting these molecular pathways.

Main Methods:

• Analysis of molecular mechanisms involving protein synthesis and degradation pathways in muscle.
• Assessment of reactive oxygen species (ROS) and inflammatory cytokine levels in muscle tissue.
• Investigation of the impact of uremic toxins, including indoxyl sulfate, on muscle-specific ubiquitin ligases (e.g., atrogin-1) and mitochondrial function.

Main Results:

• Muscle wasting in CKD is driven by increased protein degradation, elevated ROS, and inflammatory cytokines.
• Myostatin signaling, induced by ROS and inflammation, upregulates atrogenes like atrogin-1 and muscle ring factor 1.
• Indoxyl sulfate, a protein-bound uremic toxin, promotes muscle atrophy via ROS-mediated pathways and impairs mitochondrial function.

Conclusions:

• CKD-induced muscle wasting involves complex molecular pathways including oxidative stress, inflammation, and specific uremic toxins.
• Indoxyl sulfate plays a significant role in driving muscle atrophy and mitochondrial dysfunction in CKD.
• Targeting these molecular mechanisms, particularly indoxyl sulfate effects, holds promise for future CKD therapeutic interventions.